查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1547545

全球血管性血友病治疗市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Von Willebrand Disease Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 222 Pages | 商品交期: 最快1-2个工作天内

价格

全球血管性血友病治疗市场需求预计将从2023年的6.0192亿美元达到2032年近10.6541亿美元的市场规模，2024-2032年研究期间复合年增长率为6.55%。

冯维勒布兰氏症 (VWD) 是由一种称为冯维勒布兰德因子 (VWF) 的蛋白质缺乏或功能障碍引起的。这是一种常见的遗传性出血疾病。 VWF 的作用是与血管壁中的因子 VIII（一种关键的凝血蛋白）和血小板结合，并在凝血过程中帮助形成血小板栓。在冯维勒布兰氏症中，凝血过程被延迟，导致受伤时失血过多。血管性血友病患者有多种治疗方法，包括荷尔蒙疗法和非荷尔蒙疗法。

市场动态

由于冯·维勒布兰德病在全球范围内的高盛行率，该市场正在不断增长。 2019年，预计残疾人士将影响约1%的总人口；然而，具有临床意义的疾病盛行率预计约为每百万人 125 人，每百万人中最多有 5 人患有严重疾病。根据世界血友病联合会 2017 年进行的全球调查，全球有 76,144 人受到血管性血友病 (vWD) 的影响。对血管性血友病（VWD）的认识不断提高以及患者援助计划的增加也推动了市场的成长。冯维勒布兰氏症 (VWD) 是一种罕见的遗传性疾病，可能无法诊断，需要患者援助计划提高意识。因此，许多组织和公司都致力于提高人们对血管性血友病的认识。例如，美国血液学会（ASH）采取了多项倡议，例如在拉丁美洲建立临床研究培训机构、实施全球研究奖和访客培训计划，预计将在预测期内推动市场的成长。然而，高昂的治疗费用对于血管性血友病（VWD）患者来说是一项重大挑战。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球血管性血友病治疗市场的每个细分市场进行了包容性评估。血管性血友病治疗产业的成长和趋势为本研究提供了整体方法。

市场区隔

冯维勒布兰德疾病治疗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人口统计数据以及即将到来的机会。

依疾病类型

  • 1 型血管性血友病
  • 2 型血管性血友病
  • 3 型血管性血友病
  • 后天性血管性血友病

按药物分类

  • 去氨加压素
  • 凝血稳定药物
  • 替代疗法
  • 避孕药具
  • 其他的

依给药途径

  • 口服
  • 注射
  • 其他的

按性别

  • 男士
  • 女性

按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的血管性血友病治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。冯维勒布兰德疾病治疗市场的主要参与者包括 Octapharma AG、Grifols, SA.、Shire Plc、Bayer AG、CSL Behring、Pfizer Inc.、Ako Inc.、Ferring BV。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：血管性血友病治疗 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按疾病类型分類的市场吸引力分析
    • 药品市场吸引力分析
    • 按给药途径进行的市场吸引力分析
    • 按性别分類的市场吸引力分析
    • 按配销通路分類的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球血管性血友病治疗市场分析：依疾病类型

  • 依疾病类型概述
  • 按疾病类型进行历史和预测资料分析
  • 1 型血管性血友病
  • 2 型血管性血友病
  • 3 型血管性血友病
  • 后天性血管性血友病

第 6 章：全球血管性血友病治疗市场分析：依药物分类

  • 按药物概述
  • 按药物的历史和预测数据分析
  • 去氨加压素
  • 凝血稳定药物
  • 替代疗法
  • 避孕药具
  • 其他的

第 7 章：全球血管性血友病治疗市场分析：依给药途径

  • 依给药途径概述
  • 按给药途径进行历史和预测资料分析
  • 口服
  • 注射
  • 其他的

第 8 章：全球血管性血友病治疗市场分析：依性别

  • 按性别分類的概述
  • 按性别分類的历史和预测资料分析
  • 男士
  • 女性

第 9 章：全球血管性血友病治疗市场分析：按分销管道

  • 配销通路概览
  • 按配销通路进行历史和预测资料分析
  • 医院药房
  • 零售药局
  • 网路药局

第 10 章：全球血管性血友病治疗市场分析：依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 11 章：血管性血友病治疗公司的竞争格局

  • 冯维勒布兰德疾病治疗市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 12 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • Octapharma AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Grifols SA.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Ferring BV
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Shire Plc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bayer AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • CSL Behring
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Pfizer Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Ako Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR11215007

The global demand for Von Willebrand Disease Treatment Market is presumed to reach the market size of nearly USD 1065.41 Million by 2032 from USD 601.92 Million in 2023 with a CAGR of 6.55% under the study period 2024-2032.

Von Willebrand disease (VWD) is caused by a deficiency or dysfunctioning of a protein known as von Willebrand factor (VWF). It is a common genetic hemorrhagic disorder. The role of VWF is to binds with factor VIII(a key clotting protein) and platelets in blood vessel walls, and help form a platelet plug during the clotting process. In Von Willebrand disease the clotting process is delayed and leads to high blood loss in the incidence of injury. There are many treatments available for patients with von Willebrand disease including hormonal and non-hormonal therapies.

MARKET DYNAMICS

The market is growing due to the high prevalence of von Willebrand disease globally. In 2019, the PWD was projected to affect about 1% of the general population; however, clinically significant disease prevalence is predicted to be about 125 per million, with severe disease affecting up to 5 people per million. As per World Federation of Hemophilia's global survey conducted in the year 2017, 76,144 people were affected by von Willebrand disease (vWD) across the world. The rising awareness of von Willebrand disease (VWD) and increasing patient assistance programs are also driving the growth of the market. Von Willebrand disease (VWD) is a rare hereditary that may not be diagnosed and requires awareness in patient assistance programs. Therefore, many organizations and companies are focusing on increasing awareness among people about von Willebrand's disease. For example, the American Society of Hematology (ASH) takes several initiatives such as establishing the clinical research training institute in Latin America, implementing a global research award, and visitor training program, which is expected to boost the market's growth during the forecast period. However, the high cost of treatment is a significant challenge for patients with von Willebrand disease (VWD).

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Von Willebrand Disease Treatment. The growth and trends of Von Willebrand Disease Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Von Willebrand Disease Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Type

  • Type 1 Von Willebrand Disease
  • Type 2 Von Willebrand Disease
  • Type 3 Von Willebrand Disease
  • Acquired Von Willebrand Disease

By Drug

  • Desmopressin
  • Clotstabilizing Medications
  • Replacement Therapies
  • Contraceptives
  • Others

By Route of Administration

  • Oral
  • Injection
  • Others

By Gender

  • Men
  • Women

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Von Willebrand Disease Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Von Willebrand Disease Treatment market include Octapharma AG, Grifols, SA., Shire Plc, Bayer AG, CSL Behring, Pfizer Inc., Ako Inc., Ferring BV. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. VON WILLEBRAND DISEASE TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Disease Type
    • 3.7.2 Market Attractiveness Analysis By Drug
    • 3.7.3 Market Attractiveness Analysis By Route of Administration
    • 3.7.4 Market Attractiveness Analysis By Gender
    • 3.7.5 Market Attractiveness Analysis By Distribution Channel
    • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY DISEASE TYPE

  • 5.1. Overview By Disease Type
  • 5.2. Historical and Forecast Data Analysis By Disease Type
  • 5.3. Type 1 Von Willebrand Disease Historic and Forecast Sales By Regions
  • 5.4. Type 2 Von Willebrand Disease Historic and Forecast Sales By Regions
  • 5.5. Type 3 Von Willebrand Disease Historic and Forecast Sales By Regions
  • 5.6. Acquired Von Willebrand Disease Historic and Forecast Sales By Regions

6. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY DRUG

  • 6.1. Overview By Drug
  • 6.2. Historical and Forecast Data Analysis By Drug
  • 6.3. Desmopressin Historic and Forecast Sales By Regions
  • 6.4. Clotstabilizing Medications Historic and Forecast Sales By Regions
  • 6.5. Replacement Therapies Historic and Forecast Sales By Regions
  • 6.6. Contraceptives Historic and Forecast Sales By Regions
  • 6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 7.1. Overview By Route of Administration
  • 7.2. Historical and Forecast Data Analysis By Route of Administration
  • 7.3. Oral Historic and Forecast Sales By Regions
  • 7.4. Injection Historic and Forecast Sales By Regions
  • 7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY GENDER

  • 8.1. Overview By Gender
  • 8.2. Historical and Forecast Data Analysis By Gender
  • 8.3. Men Historic and Forecast Sales By Regions
  • 8.4. Women Historic and Forecast Sales By Regions

9. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 9.1. Overview By Distribution Channel
  • 9.2. Historical and Forecast Data Analysis By Distribution Channel
  • 9.3. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 9.4. Retail Pharmacies Historic and Forecast Sales By Regions
  • 9.5. Online Pharmacies Historic and Forecast Sales By Regions

10. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2 North America By Segment Sales Analysis
    • 10.3.3 North America By Country Sales Analysis
    • 10.3.4 United States Sales Analysis
    • 10.3.5 Canada Sales Analysis
    • 10.3.6 Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2 Europe By Segment Sales Analysis
    • 10.4.3 Europe By Country Sales Analysis
    • 10.4.4 United Kingdom Sales Analysis
    • 10.4.5 France Sales Analysis
    • 10.4.6 Germany Sales Analysis
    • 10.4.7 Italy Sales Analysis
    • 10.4.8 Russia Sales Analysis
    • 10.4.9 Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2 Asia Pacific By Segment Sales Analysis
    • 10.5.3 Asia Pacific By Country Sales Analysis
    • 10.5.4 China Sales Analysis
    • 10.5.5 India Sales Analysis
    • 10.5.6 Japan Sales Analysis
    • 10.5.7 South Korea Sales Analysis
    • 10.5.8 Australia Sales Analysis
    • 10.5.9 South East Asia Sales Analysis
    • 10.5.10 Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2 Latin America By Segment Sales Analysis
    • 10.6.3 Latin America By Country Sales Analysis
    • 10.6.4 Brazil Sales Analysis
    • 10.6.5 Argentina Sales Analysis
    • 10.6.6 Peru Sales Analysis
    • 10.6.7 Chile Sales Analysis
    • 10.6.8 Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2 Middle East & Africa By Segment Sales Analysis
    • 10.7.3 Middle East & Africa By Country Sales Analysis
    • 10.7.4 Saudi Arabia Sales Analysis
    • 10.7.5 UAE Sales Analysis
    • 10.7.6 Israel Sales Analysis
    • 10.7.7 South Africa Sales Analysis
    • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE VON WILLEBRAND DISEASE TREATMENT COMPANIES

  • 11.1. Von Willebrand Disease Treatment Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12. COMPANY PROFILES OF VON WILLEBRAND DISEASE TREATMENT INDUSTRY

  • 12.1. Top Companies Market Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. Octapharma AG
    • 12.3.1 Company Overview
    • 12.3.2 Company Revenue
    • 12.3.3 Products
    • 12.3.4 Recent Developments
  • 12.4. Grifols SA.
    • 12.4.1 Company Overview
    • 12.4.2 Company Revenue
    • 12.4.3 Products
    • 12.4.4 Recent Developments
  • 12.5. Ferring BV
    • 12.5.1 Company Overview
    • 12.5.2 Company Revenue
    • 12.5.3 Products
    • 12.5.4 Recent Developments
  • 12.6. Shire Plc
    • 12.6.1 Company Overview
    • 12.6.2 Company Revenue
    • 12.6.3 Products
    • 12.6.4 Recent Developments
  • 12.7. Bayer AG
    • 12.7.1 Company Overview
    • 12.7.2 Company Revenue
    • 12.7.3 Products
    • 12.7.4 Recent Developments
  • 12.8. CSL Behring
    • 12.8.1 Company Overview
    • 12.8.2 Company Revenue
    • 12.8.3 Products
    • 12.8.4 Recent Developments
  • 12.9. Pfizer Inc.
    • 12.9.1 Company Overview
    • 12.9.2 Company Revenue
    • 12.9.3 Products
    • 12.9.4 Recent Developments
  • 12.10. Ako Inc.
    • 12.10.1 Company Overview
    • 12.10.2 Company Revenue
    • 12.10.3 Products
    • 12.10.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Disease Type (USD MN)
  • Type 1 Von Willebrand Disease Market Sales By Geography (USD MN)
  • Type 2 Von Willebrand Disease Market Sales By Geography (USD MN)
  • Type 3 Von Willebrand Disease Market Sales By Geography (USD MN)
  • Acquired Von Willebrand Disease Market Sales By Geography (USD MN)
  • Analysis By Drug (USD MN)
  • Desmopressin Market Sales By Geography (USD MN)
  • Clotstabilizing Medications Market Sales By Geography (USD MN)
  • Replacement Therapies Market Sales By Geography (USD MN)
  • Contraceptives Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Injection Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Gender (USD MN)
  • Men Market Sales By Geography (USD MN)
  • Women Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Global Von Willebrand Disease Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Von Willebrand Disease Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Von Willebrand Disease Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Disease Type
  • Market Attractiveness Analysis By Drug
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By Gender
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Disease Type (USD MN)
  • Type 1 Von Willebrand Disease Market Sales By Geography (USD MN)
  • Type 2 Von Willebrand Disease Market Sales By Geography (USD MN)
  • Type 3 Von Willebrand Disease Market Sales By Geography (USD MN)
  • Acquired Von Willebrand Disease Market Sales By Geography (USD MN)
  • Global Market Analysis By Drug (USD MN)
  • Desmopressin Market Sales By Geography (USD MN)
  • Clotstabilizing Medications Market Sales By Geography (USD MN)
  • Replacement Therapies Market Sales By Geography (USD MN)
  • Contraceptives Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Injection Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Gender (USD MN)
  • Men Market Sales By Geography (USD MN)
  • Women Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.